Jefferies on Insmed (INSM): UTHR data 'validates inhaled prostacyclin class in IPF,' INSM's TPIP potl BIC
Tweet Send to a Friend
Jefferies analyst Faisal Khurshid reiterated a Buy rating and $230.00 price target on Insmed (NASDAQ: INSM)The analyst commented, "UTHR reported ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
